DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR CIPROFLOXACIN AND DEXAMETHASONE
» See Plans and Pricing
All Clinical Trials for Ciprofloxacin And Dexamethasone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00477412 | Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma | Active, not recruiting | Millennium Pharmaceuticals, Inc. | Phase 1 | 2007-04-01 | The goal of this clinical research study is to learn if bortezomib (in combination with rituximab plus 2 different intensive chemotherapy regimens) can help to control the disease in patients with mantle cell lymphoma. The safety of these drug combinations will also be studied. |
| NCT00477412 | Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma | Active, not recruiting | M.D. Anderson Cancer Center | Phase 1 | 2007-04-01 | The goal of this clinical research study is to learn if bortezomib (in combination with rituximab plus 2 different intensive chemotherapy regimens) can help to control the disease in patients with mantle cell lymphoma. The safety of these drug combinations will also be studied. |
| NCT00945802 | FST-201 In The Treatment of Acute Otitis Externa | Terminated | Shire | Phase 3 | 2009-07-01 | The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute otitis externa. |
| NCT00956748 | N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media | Not yet recruiting | St. Paul's Hospital, Canada | Phase 4 | 2016-06-01 | Chronic suppurative otitis media (CSOM) can be particularly difficult to treat as a number of patients do not respond to routine antibiotic or surgical treatments. The current treatment involves administering combination antibiotic anti-inflammatory ear drops such as Ciprodex (ciprofloxacin 0.3% / dexamethasone 0.1%). Although most patients experience a relief of symptoms, a fraction of patients remain refractory to treatment. Recent findings suggest that the addition of N-acetylcysteine (0.5-2%) to Ciprodex is a superior treatment for otitis media with effusion compared to the use of Ciprodex alone. |
| NCT00961675 | FST-201 in the Treatment of Acute Otitis Externa | Completed | Shire | Phase 3 | 2009-08-01 | The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa. This study will be conducted at one site, the LBJ Tropical Medical Center, Department of Otolaryngology, in Pago Pago, American Samoa. |
| NCT01277016 | A Trial for Systemic Light-chain (AL) Amyloidosis | Completed | European Myeloma Network | Phase 3 | 2011-01-01 | In this multi-center phase III trial, untreated patients diagnosed with AL who are not candidates for stem cell transplant with melphalan 200 mg/m2 are the target population. Stage I and II patients will be eligible. Stage III patients will be enrolled in an ancillary phase II study. Eligible patients will be stratified as cardiac stage I or stage II and then randomized to receive MDex or BMDex. Primary objective is to compare hematologic(clonal) response i.e. the rate of complete response (CR) + partial response (PR) defined according to the criteria of the International Society for Amyloidosis consensus. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Ciprofloxacin And Dexamethasone
Condition Name
Condition MeSH
Clinical Trial Locations for Ciprofloxacin And Dexamethasone
Trials by Country
Clinical Trial Progress for Ciprofloxacin And Dexamethasone
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Ciprofloxacin And Dexamethasone
Sponsor Name
